Strongbridge Biopharma plc Announces $35 Million Equity Financing
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/19/2026
- Wall St rises as yields ease, Moderna lifts healthcare stocks
- U.S. Treasury doubles buyback operation size for long-dated bonds
- Marvell shares jump after giving Google warrants amid custom chip deal
- U.S. debt tops $40 trillion
- Nvidia credit risk gauge hits new peak as SoftBank readies record bond issue
- Marvell issues Google warrant tied to custom chip deal
- Tech selloff weighs down Wall Street as bond yields climb
- FOMC minutes from July 28-29th meeting
- Lowe's Cos. (LOW) Tops Q2 EPS by 17c, Misses on Revenue; Offers Fy27 Guidance
- Nvidia or Sandisk? BofA reveals which stock is under-owned and which is crowded
Strongbridge Biopharma (SBBP) Tops Q1 EPS by 12c
December 23, 2016 8:08 AM ESTStrongbridge Biopharma (NASDAQ: SBBP) reported Q1 EPS of ($0.57), $0.12 better than the analyst estimate of ($0.69).
For earnings history and earnings-related data on Strongbridge Biopharma (SBBP) click here.
... MoreStrongbridge Biopharma (SBBP) Acquires U.S. Rights to KEVEYIS
December 23, 2016 8:08 AM ESTStrongbridge Biopharma plc, (Nasdaq: SBBP), a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs, today announced that the Company has acquired the U.S. rights to KEVEYIS® (dichlorphenamide) from a subsidiary of Taro Pharmaceutical Industries Ltd. (Taro). KEVEYIS was approved by the U.S. Food and Drug Administration (FDA) in August 2015 to treat hyperkalemic, hypokalemic, and related variants of... More
